Table 3.
The antitumor efficacy of different therapeutic vaccine formulations including Buffer, Peptide, Lip-peptide, or Peptide+CpG in combination with anti PD-1 mAb in B16F10 tumor bearing mice model (N=9)
| Treatment groups | TTEa (Days±SD) | TGDb (%) | MSTc (Days) | ILSd (%) |
|---|---|---|---|---|
| Buffer | 19.54 ± 7.75 | - | 22 | - |
| Peptide | 18.97 ± 7.92 | -2.89 | 20 | -9.1 |
| Lip-peptide | 28.26 ± 13.94 | 44.65 | 22 | 0 |
| Peptide + CpG | 24.20 ± 3.36 | 23.85 | 24 | 9.09 |
| Lip-peptide + CpG | 30.03 ± 12.34 | 53.68 | 21 | -4.55 |
a Time to reach end point; b Tumor growth delay; c Median survival time; d Increased life span.